Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Inclusion Body Myositis (IBM) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Pipeline Review, H1 2015’, provides an overview of the Inclusion Body Myositis (IBM)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis (IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inclusion Body Myositis (IBM) and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Inclusion Body Myositis (IBM) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Inclusion Body Myositis (IBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Inclusion Body Myositis (IBM) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Inclusion Body Myositis (IBM) Overview 6 Therapeutics Development 7 Pipeline Products for Inclusion Body Myositis (IBM) - Overview 7 Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis 8 Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies 9 Inclusion Body Myositis (IBM) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Inclusion Body Myositis (IBM) - Products under Development by Companies 12 Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development 13 Acceleron Pharma, Inc. 13 New Zealand Pharmaceuticals Limited 14 Nobelpharma Co., Ltd. 15 Novartis AG 16 Ultragenyx Pharmaceutical Inc. 17 Inclusion Body Myositis (IBM) - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AAV1-Foliistatin - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ACE-083 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 aceneuramic acid - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 bimagrumab - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 DEXM-74 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 UX-007 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Inclusion Body Myositis (IBM) - Recent Pipeline Updates 36 Inclusion Body Myositis (IBM) - Dormant Projects 43 Inclusion Body Myositis (IBM) - Product Development Milestones 44 Featured News & Press Releases 44 Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy 44 Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society 45 Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting 45 Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy 47 Oct 02, 2013: MorphoSys Collaborator to Start Pivotal Study with Bimagrumab 47 Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress 48 Aug 20, 2013: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) 48 Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy 49 Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Number of Products under Development for Inclusion Body Myositis (IBM), H1 2015 7 Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma, Inc., H1 2015 13 Inclusion Body Myositis (IBM) - Pipeline by New Zealand Pharmaceuticals Limited, H1 2015 14 Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co., Ltd., H1 2015 15 Inclusion Body Myositis (IBM) - Pipeline by Novartis AG, H1 2015 16 Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 17 Assessment by Monotherapy Products, H1 2015 18 Number of Products by Stage and Target, H1 2015 20 Number of Products by Stage and Mechanism of Action, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 Inclusion Body Myositis (IBM) Therapeutics - Recent Pipeline Updates, H1 2015 36 Inclusion Body Myositis (IBM) - Dormant Projects, H1 2015 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.